257 related articles for article (PubMed ID: 6149904)
21. Comparative disposition of phosphoramide mustard and other cyclophosphamide metabolites in the mouse using the Salmonella/mutagenesis assay.
Suling WJ; Struck RF; Woolley CW; Shannon WM
Cancer Treat Rep; 1978 Sep; 62(9):1321-8. PubMed ID: 356985
[No Abstract] [Full Text] [Related]
22. Blood levels of alkylating metabolites of cyclophosphamide in the mouse after iv or oral administration.
Struck RF; Alberts DS
Cancer Treat Rep; 1984 May; 68(5):765-70. PubMed ID: 6722832
[TBL] [Abstract][Full Text] [Related]
23. Analysis of 4-hydroxycyclophosphamide by gas chromatography-mass spectrometry in plasma.
Hong PS; Chan KK
J Chromatogr; 1989 Oct; 495():131-8. PubMed ID: 2613798
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxicity and DNA cross-linking activity of 4-sulfidocyclophosphamides in mouse leukemia cells in vitro.
Erickson LC; Ramonas LM; Zaharko DS; Kohn KW
Cancer Res; 1980 Nov; 40(11):4216-20. PubMed ID: 7471062
[TBL] [Abstract][Full Text] [Related]
25. NADPH-dependent enzyme-catalyzed reduction of aldophosphamide, the pivotal metabolite of cyclophosphamide.
Parekh HK; Sladek NE
Biochem Pharmacol; 1993 Sep; 46(6):1043-52. PubMed ID: 8216347
[TBL] [Abstract][Full Text] [Related]
26. The interaction of glutathione with 4-hydroxycyclophosphamide and phosphoramide mustard, studied by 31P nuclear magnetic resonance spectroscopy.
Dirven HA; Venekamp JC; van Ommen B; van Bladeren PJ
Chem Biol Interact; 1994 Dec; 93(3):185-96. PubMed ID: 7923439
[TBL] [Abstract][Full Text] [Related]
27. O-Methylhydroxylamine as a new trapping reagent for quantitative studies of 4-hydroxycyclophosphamide and aldophosphamide.
Zon G; Ludeman SM; Sweet EM; Egan W; Phillips LR
J Pharm Sci; 1982 Apr; 71(4):443-6. PubMed ID: 7086655
[TBL] [Abstract][Full Text] [Related]
28. Influence of diuretics on urinary general base catalytic activity and cyclophosphamide-induced bladder toxicity.
Sladek NE; Smith PC; Bratt PM; Low JE; Powers JF; Borch RF; Coveney JR
Cancer Treat Rep; 1982 Nov; 66(11):1889-1900. PubMed ID: 7139634
[TBL] [Abstract][Full Text] [Related]
29. Vomiting induced by cyclophosphamide and phosphoramide mustard in cats.
Fetting JH; McCarthy LE; Borison HL; Colvin M
Cancer Treat Rep; 1982 Aug; 66(8):1625-9. PubMed ID: 7105052
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients.
Ren S; Kalhorn TF; McDonald GB; Anasetti C; Appelbaum FR; Slattery JT
Clin Pharmacol Ther; 1998 Sep; 64(3):289-301. PubMed ID: 9757153
[TBL] [Abstract][Full Text] [Related]
31. Kinetic characterization of the catalysis of "activated" cyclophosphamide (4-hydroxycyclophosphamide/aldophosphamide) oxidation to carboxyphosphamide by mouse hepatic aldehyde dehydrogenases.
Manthey CL; Sladek NE
Biochem Pharmacol; 1988 Jul; 37(14):2781-90. PubMed ID: 3395357
[TBL] [Abstract][Full Text] [Related]
32. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy.
Jardine I; Fenselau C; Appler M; Kan MN; Brundrett RB; Colvin M
Cancer Res; 1978 Feb; 38(2):408-15. PubMed ID: 620410
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the mutagenicity and teratogenicity of cyclophosphamide and its active metabolites, 4-hydroxycyclophosphamide, phosphoramide mustard, and acrolein.
Hales BF
Cancer Res; 1982 Aug; 42(8):3016-21. PubMed ID: 7046914
[No Abstract] [Full Text] [Related]
34. Thermodynamic analysis of the reaction of phosphoramide mustard with protector thiols.
Seitz DE; Katterjohn CJ; Rinzel SM; Pearce HL
Cancer Res; 1989 Jul; 49(13):3525-8. PubMed ID: 2499418
[TBL] [Abstract][Full Text] [Related]
35. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
Anderson LW; Chen TL; Colvin OM; Grochow LB; Collins JM; Kennedy MJ; Strong JM
Clin Cancer Res; 1996 Sep; 2(9):1481-7. PubMed ID: 9816324
[TBL] [Abstract][Full Text] [Related]
36. In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity.
Yu LJ; Drewes P; Gustafsson K; Brain EG; Hecht JE; Waxman DJ
J Pharmacol Exp Ther; 1999 Mar; 288(3):928-37. PubMed ID: 10027828
[TBL] [Abstract][Full Text] [Related]
37. [Blood level and urinary excretion of activated cyclophosphamide and its deactivation products in man (author's transl)].
Wagner T; Heydrich D; Voelcker G; Hohorst HJ
J Cancer Res Clin Oncol; 1980 Jan; 96(1):79-92. PubMed ID: 7358774
[TBL] [Abstract][Full Text] [Related]
38. Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite.
Struck RF; Kirk MC; Witt MH; Laster WR
Biomed Mass Spectrom; 1975 Feb; 2(1):46-52. PubMed ID: 1131393
[TBL] [Abstract][Full Text] [Related]
39. Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial.
Struck RF; Alberts DS; Horne K; Phillips JG; Peng YM; Roe DJ
Cancer Res; 1987 May; 47(10):2723-6. PubMed ID: 3552204
[TBL] [Abstract][Full Text] [Related]
40. Identification and pharmacokinetics of cyclophosphamide (NSC-26271) metabolites in vivo.
Voelcker G; Wagner T; Hohorst HJ
Cancer Treat Rep; 1976 Apr; 60(4):415-22. PubMed ID: 1277216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]